Page last updated: 2024-10-25

deferoxamine and Acute Coronary Syndrome

deferoxamine has been researched along with Acute Coronary Syndrome in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fan, Y1
Wang, J1
Wei, L1
He, B1
Wang, C1
Wang, B1

Other Studies

1 other study available for deferoxamine and Acute Coronary Syndrome

ArticleYear
Iron deficiency activates pro-inflammatory signaling in macrophages and foam cells via the p38 MAPK-NF-κB pathway.
    International journal of cardiology, 2011, Oct-06, Volume: 152, Issue:1

    Topics: Acute Coronary Syndrome; Atherosclerosis; Basigin; Cell Line; Deferoxamine; Foam Cells; Gene Express

2011